Christopher M. Treleaven

1.6k total citations
19 papers, 1.2k citations indexed

About

Christopher M. Treleaven is a scholar working on Neurology, Molecular Biology and Physiology. According to data from OpenAlex, Christopher M. Treleaven has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Neurology, 8 papers in Molecular Biology and 8 papers in Physiology. Recurrent topics in Christopher M. Treleaven's work include Lysosomal Storage Disorders Research (8 papers), Amyotrophic Lateral Sclerosis Research (6 papers) and Neurogenetic and Muscular Disorders Research (5 papers). Christopher M. Treleaven is often cited by papers focused on Lysosomal Storage Disorders Research (8 papers), Amyotrophic Lateral Sclerosis Research (6 papers) and Neurogenetic and Muscular Disorders Research (5 papers). Christopher M. Treleaven collaborates with scholars based in United States and France. Christopher M. Treleaven's co-authors include Seng H. Cheng, Lamya S. Shihabuddin, James C. Dodge, S. Pablo Sardi, Tatyana V. Taksir, Richard L. Sidman, Marco A. Passini, Jennifer Clarke, Thomas J. Tamsett and Jonathan A. Fidler and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and PLoS ONE.

In The Last Decade

Christopher M. Treleaven

19 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher M. Treleaven United States 16 641 489 469 298 240 19 1.2k
Kathleen M. Schoch United States 16 432 0.7× 666 1.4× 462 1.0× 347 1.2× 284 1.2× 24 1.5k
Giulietta Riboldi Italy 19 432 0.7× 846 1.7× 226 0.5× 353 1.2× 393 1.6× 43 1.4k
Julien Couthouis United States 16 418 0.7× 595 1.2× 217 0.5× 186 0.6× 175 0.7× 22 1.1k
Hidetoshi Date Japan 14 424 0.7× 764 1.6× 184 0.4× 546 1.8× 93 0.4× 20 1.2k
Toni Williamson United States 12 657 1.0× 413 0.8× 206 0.4× 409 1.4× 372 1.6× 21 1.3k
Alexander E. Volk Germany 19 761 1.2× 563 1.2× 216 0.5× 183 0.6× 533 2.2× 43 1.4k
Basar Cenik United States 10 930 1.5× 733 1.5× 274 0.6× 115 0.4× 440 1.8× 13 1.4k
Tracy Cole United States 11 601 0.9× 368 0.8× 477 1.0× 262 0.9× 149 0.6× 16 1.2k
Sorana Ciura France 13 726 1.1× 427 0.9× 165 0.4× 177 0.6× 398 1.7× 19 1.1k
Yongping Chen China 23 1.2k 1.8× 530 1.1× 252 0.5× 298 1.0× 463 1.9× 121 1.7k

Countries citing papers authored by Christopher M. Treleaven

Since Specialization
Citations

This map shows the geographic impact of Christopher M. Treleaven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher M. Treleaven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher M. Treleaven more than expected).

Fields of papers citing papers by Christopher M. Treleaven

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher M. Treleaven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher M. Treleaven. The network helps show where Christopher M. Treleaven may publish in the future.

Co-authorship network of co-authors of Christopher M. Treleaven

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher M. Treleaven. A scholar is included among the top collaborators of Christopher M. Treleaven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher M. Treleaven. Christopher M. Treleaven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Dodge, James C., Thomas J. Tamsett, Christopher M. Treleaven, et al.. (2022). Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer’s disease. Alzheimer s Research & Therapy. 14(1). 19–19. 15 indexed citations
2.
Sardi, S. Pablo, Catherine Viel, Jennifer Clarke, et al.. (2017). Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proceedings of the National Academy of Sciences. 114(10). 2699–2704. 161 indexed citations
3.
Rockenstein, Edward, Jennifer Clarke, Catherine Viel, et al.. (2016). Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson’s disease. Human Molecular Genetics. 25(13). ddw124–ddw124. 42 indexed citations
4.
Dodge, James C., Christopher M. Treleaven, Joshua Pacheco, et al.. (2015). Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences. 112(26). 8100–8105. 102 indexed citations
5.
Passini, Marco A., Jie Bu, Amy M. Richards, et al.. (2014). Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9–Survival Motor Neuron 1 for Spinal Muscular Atrophy. Human Gene Therapy. 25(7). 619–630. 72 indexed citations
6.
Havari, Evis, Michael J. Turner, James C. Dodge, et al.. (2014). Anti-murine CD52 antibody treatment does not adversely affect the migratory ability of immune cells. Journal of Neuroimmunology. 275(1-2). 62–63. 4 indexed citations
7.
Stanek, Lisa M., S. Pablo Sardi, Christopher M. Treleaven, et al.. (2014). Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease. Human Gene Therapy. 25(5). 461–474. 126 indexed citations
8.
Havari, Evis, Michael Turner, James C. Dodge, et al.. (2014). Anti-murine CD52 Antibody Treatment Does Not Adversely Affect the Migratory Ability of Immune Cells (P1.222). Neurology. 82(10_supplement). 2 indexed citations
9.
Sardi, S. Pablo, Jennifer Clarke, Catherine Viel, et al.. (2013). Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proceedings of the National Academy of Sciences. 110(9). 3537–3542. 192 indexed citations
10.
Dodge, James C., Christopher M. Treleaven, Jonathan A. Fidler, et al.. (2013). Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proceedings of the National Academy of Sciences. 110(26). 10812–10817. 92 indexed citations
11.
Treleaven, Christopher M., Thomas J. Tamsett, Jie Bu, et al.. (2012). Gene Transfer to the CNS Is Efficacious in Immune-primed Mice Harboring Physiologically Relevant Titers of Anti-AAV Antibodies. Molecular Therapy. 20(9). 1713–1723. 27 indexed citations
12.
Treleaven, Christopher M., Thomas J. Tamsett, Jonathan A. Fidler, et al.. (2011). Comparative Analysis of Acid Sphingomyelinase Distribution in the CNS of Rats and Mice Following Intracerebroventricular Delivery. PLoS ONE. 6(1). e16313–e16313. 5 indexed citations
13.
Ziegler, Robin J., Ernesto A. Salegio, James C. Dodge, et al.. (2011). Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion. Experimental Neurology. 231(2). 261–271. 23 indexed citations
14.
Fidler, Jonathan A., Christopher M. Treleaven, Thomas J. Tamsett, et al.. (2011). Disease progression in a mouse model of amyotrophic lateral sclerosis: the influence of chronic stress and corticosterone. The FASEB Journal. 25(12). 4369–4377. 26 indexed citations
15.
Sidman, Richard L., Tatyana V. Taksir, Christopher M. Treleaven, et al.. (2010). Relationship between neuropathology and disease progression in the SOD1G93A ALS mouse. Experimental Neurology. 227(2). 287–295. 38 indexed citations
16.
Dodge, James C., Christopher M. Treleaven, Jonathan A. Fidler, et al.. (2010). AAV4-mediated Expression of IGF-1 and VEGF Within Cellular Components of the Ventricular System Improves Survival Outcome in Familial ALS Mice. Molecular Therapy. 18(12). 2075–2084. 104 indexed citations
17.
Dodge, James C., Amanda M. Haidet, Wendy Yang, et al.. (2008). Delivery of AAV-IGF-1 to the CNS Extends Survival in ALS Mice Through Modification of Aberrant Glial Cell Activity. Molecular Therapy. 16(6). 1056–1064. 128 indexed citations
18.
Dodge, James C., Jennifer Clarke, Christopher M. Treleaven, et al.. (2008). Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann–Pick A disease. Experimental Neurology. 215(2). 349–357. 60 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathleen M. Schoch Breakdown of academic impact, for papers by Giulietta Riboldi Breakdown of academic impact, for papers by Julien Couthouis Breakdown of academic impact, for papers by Hidetoshi Date Breakdown of academic impact, for papers by Toni Williamson Breakdown of academic impact, for papers by Alexander E. Volk Breakdown of academic impact, for papers by Basar Cenik Breakdown of academic impact, for papers by Tracy Cole Breakdown of academic impact, for papers by Sorana Ciura Breakdown of academic impact, for papers by Yongping Chen
Rankless by CCL
2026